Credit Suisse’s Kyntra Bio KYNB Stock Holding History

Credit Suisse’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,364	Closed	-$1.26M	–	4378
2020 Q4	$1.26M	Buy	+1,364	New	+$1.43M	﹤0.01%	3159
2020 Q3	–	Sell	-788	Closed	-$798K	–	4050
2020 Q2	$798K	Buy	+788	New	+$732K	﹤0.01%	3036

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's KYNB Position: Q3 2023 in Review

Credit Suisse sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 4,244 shares — an estimated $286K sold.

Credit Suisse first reported a position in KYNB in Q1 2015 and held it in 34 quarters. The position peaked at $42M in Q2 2018. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

Credit Suisse reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
Credit Suisse sold 4,244 Kyntra Bio shares in Q3 2023, an estimated $286K.
Credit Suisse first reported a position in Kyntra Bio in Q1 2015 and held it in 34 quarters.
Credit Suisse's Kyntra Bio position peaked at $42M in Q2 2018.
110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.